Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein

Carcinogenesis

Volumn 17, Issue 7, 1996, Pages 1417-1427

  Gudas, Jean M ^a,c   Nguyen, Hoang ^b   Li, Tao ^b   Sadzewicz, Lisa ^b   Robey, Robert ^a   Wosikowksi, Katja ^a   Cowan, Kenneth H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Oncor Inc   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; MELPHALAN; MESSENGER RNA; MITOXANTRONE; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SPARFOSIC ACID;

ARTICLE; BREAST CANCER; CELL CYCLE G1 PHASE; CELL STRAIN MCF 7; CONTROLLED STUDY; DELETION MUTANT; HETEROZYGOTE; HUMAN; HUMAN CELL; IONIZING RADIATION; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; ASPARTIC ACID; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CLONE CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MELPHALAN; MITOXANTRONE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHOSPHONOACETIC ACID; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RIBONUCLEOSIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029947671     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.7.1417     Document Type: Article

References (94)

1. Assaraf, Y.G. and Schimke, R.T. (1987) Identification of methotrexate transport deficiency in mammalian cells using fluoresceinated methotrexate and flow cytometry. Proc. Natl Acad. Sci. USA, 84, 7154-7158.
2. Simonsen, C.C. and Levinson, A.D. (1983) Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc. Natl Acad. Sci. USA, 80, 2495-2499.
3. Thillet, J., Absil, J., Stone, S.R. and Pictet, R. (1988) Site directed mutagenesis of mouse dihydrofolate reductase: mutants with increased resistance to methotrexate and trimethopterin. J. Biol. Chem., 263, 12500-12508.
4. Alt, F.W., Kellems, R.E., Bertino, J.R. and Schimke, R.T. (1978) Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol. Chem., 253, 1357-1370.
5. Melera, P.W., Lewis, J.A., Biedler, J.L. and Hession, C. (1980) Antifolate-resistant Chinese hamster cells: evidence for dihyrofolate reducatase gene amplification among independently derived sublines overproducing different dihydrofolate reductases. J. Biol. Chem., 255, 7024-7028.
6. Moscow, J.A., Schneider, E. and Cowan, K.H. (1994) Multidrug resistance. In Pinedo, H.M., Longo, D.L. and Chabner, B.A. (eds), Cancer Chemotherapy and Biological Response Modifiers Annual 15. Elselvier Science, pp. 99-129.
7. Mansouri, A., Henle, K.J. and Nagle, W.A. (1994) Tumor drug-resistance: a challenge to therapists and biologists. Am. J. Med. Sci., 307, 438-444.
8. Hartwell, L.H. and Kastan, M.B. (1994) Cell cycle control and cancer. Science, 266, 1821-1828.
9. Hartwell, L. (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71, 543-546.
10. Schwab, M. (1990) Oncogene amplification in neoplastic development and progression of human cancers. Crit. Rev. Oncogen., 2, 35.
11. Wright, J.A., Smith, H.S., Watt, F.M., Hancock, M.C., Hudson, D.L. and Stark, G.R. (1990) DNA amplification is rare in normal human cells. Proc. Natl Acad. Sci. USA, 87, 1791-1795.
12. Tlsty, T.D., Margolin, B.H. and Lum, K. (1989) Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbruck fluctuation analysis. Proc. Natl Acad. Sci. USA, 86, 9441-9445.
13. Sager, R., Gadi, I., Stephens, L. and Grabowy, C.T. (1985) Gene amplification: an example of accelerated evolution in tumorigenic cells. Proc. Natl Acad. Sci. USA, 82, 7015-7019.
14. Wahl, G.M., Padgett, R.A. and Stark, G.R. (1979) Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-apartate resistant hamster cells. J. Biol. Chem., 254, 8679-8689.
15. Di Leonardo, A., Linke, S.P., Yin, Y. and Wahl, G.M. (1993) Cell cycle regulation of gene amplification. Cold Spring Harbor Symp. Quant. Biol., 58, 655-667.
16. Livingstone, L.R., White, A., Sprouse, J., Livanos, E., Jacks, T. and Tlsty, T.D. (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-936.
17. Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C. and Wahl, G.M. (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.
18. Weibe, V.J., Osborne, C.K., Fuqua, S.A. and DeGregorio, M.W. (1993) Tamoxifen resistance in breast cancer. Crit. Rev. Oncol. Hematol., 14, 173-188.
19. Morrow, M. and Jordan, V.C. (1993) Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch. Surg., 128, 1187-1191.
20. Cowan, K.H., Goldsmith, M.E., Levine, R.M., Aitken, S.C., Douglass, E., Clendeinn, N., Nienhaus, A.W. and Lippman, M.E. (1982) Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J. Biol. Chem., 257, 15079-15086.
21. Cowan, K.H., Batist, G., Tulpule, A., Sinha, B.K. and Myers, C.E. (1986) Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc. Natl Acad. Sci. USA, 83, 9328-9332.
22. Moscow, J.A., Swanson, C.A. and Cowan, K.H. (1993) Decreased melphalan accumulation in a breast cancer line selected for resistance to melphalan. Br. J. Cancer, 68, 732-737.
23. Nakagawa, M., Schneider, E., Dixon, K.H., Horton, J., Kelley, K., Morrow, C. and Cowan, K.H. (1992) Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res., 52, 6175-6181.
24. Schneider, E., Horton, J.K., Yang, C.-H., Nakagawa, M. and Cowan, K.H. (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54, 152-158.
25. Vickers, P.P., Dixon, R.B. and Cowan, K.H. (1988) A pleiotropic response associated with resistance of breast cancer cells to antineoplastic drugs and hormonal agents. Trends Pharmacol. Sci., 9, 443-445.
26. Karle, J.M., Cowan, K.H., Chisena, C.A. and Cysyk, R.L. (1986) Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway. Am. Soc. Pharmacol. Exp. Ther., 30, 136-141.
27. Morrow, C.S. and Cowan, K.H. (1993) Antineoplastic drug resistance and breast cancer. Annls NY Acad. Sci., 698, 289-312.
28. Murnane, J.P. and Schwarz, J.L. (1993) Cell checkpoint and radiosensitivity. Nature, 365, 22.
29. Lowe, S.W., Bodis, S., McClatchey, A., Remington, L., Ruley, H.E., Fisher, D.E., Housman, D.E. and Jacks, T. (1994) p53 status and the efficacy of cancer therapy in vivo. Science, 4, 807-810.
30. Lowe, S.W., Ruley, H.E., Jacks, T. and Housman, D.E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
31. Canman, C.E. and Kastan, M.B. (1995) Induction of apoptosis by tumor suppressor genes and oncogenes. Semin. Cancer Biol., 6, 17-25.
32. Gudas, J.M., Knight, G.B. and Pardee, A.B. (1988) Nuclear post-transcriptional processing of thymidine kinase mRNA at the onset of DNA synthesis. Proc. Natl Acad. Sci. USA, 85, 4705-4709.
33. Gudas, J.M., Oka, M., Diella, F., Trepel, J. and Cowan, K.H. (1994) Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells. Cell Growth Differential., 5, 295-304.
34. Laborda, J. (1991) 36B4 cDNA as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res., 19, 3998.
35. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L. and Vogelstein, B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83.
36. Fornace, A.J., Jr, Nebert, D.W., Hollander, M.C., Luethy, J.D., Papathanasiou, M., Fargnoli, J. and Holbrook, N.J. (1989) Mammalian genes coordinately regulated by growth arrest signals and DNA damaging agents. Mol. Cell. Biol., 9, 4196-4203.
37. O'Connor, P.M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I. and Kohn, K.W. (1993) Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53, 4776-4780.
38. Ishioka, C., Frebourg, T., Yan, Y.-X., Vidal, M., Friend, S.H., Schmidt, S. and Iggo, R. (1993) Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nature Genet., 5, 124-129.
39. Frebourg, T. (1992) A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res., 52, 6976-6978.
40. Wazer, D.E., Chu, Q., Liu, X.-L., Gao, Q., Safaii, H. and Band, V. (1994) Loss of p53 protein during radiation transformation of primary mammary epithelial cells. Mol. Cell. Biol., 14, 2468-2478.
41. Di Leonardo, A., Linke, S.P., Clarkin, K. and Wahl, G.M. (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of CIP1 in normal human fibroblasts. Genes Dev., 8, 2540-2551.
42. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R.W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
43. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V. and Kastan, M.B. (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 89, 7491-7495.
44. Chen, C.-Y., Oliner, J.D., Zhan, Q., Fornace, A.J., Jr, Vogelstein, B. and Kastan, M.B. (1994) Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl Acad. Sci. USA, 91, 2684-2688.
45. Carrier, F., Smith, M.L., Bae, I. et al. (1994) Characterization of human Gadd 45, a p53-regulated protein. J. Biol. Chem., 269, 32672-32678.
46. Dulcic, V., Kauffman, W.K., Wilson, S.J., Tlsty, T.D., Lees, E., Harper, J.W., Elledge, S.J. and Reed, S.I. (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76, 1013-1023.
47. El-Deiry, W.S., Harper, J.W., O'Connor, P.M. et al. (1994) Waf1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
48. Kastan, M.B., Zhan, Q., El-Diery, W.S., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., Vogelstein, B. and Fornace, A.J., Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and Gadd 45 is defective in ataxiatelangiectasia. Cell, 71, 587-597.
49. Barak, Y., Juven, T., Haffner, R. and Oren, M. (1993) mdm2 expression is induced by wild type p53. EMBO J., 12, 461-468.
50. Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
51. Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132.
52. Shirodkar, S., Ewen, M., DeCaprio, J.A., Morgan, J., Livingston, D.M. and Chittenden, T. (1992) The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell, 68, 157-166.
53. Flemington, E.K., Speck, S.H. and Kaelin, W.G., Jr (1993) E2F-1 mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc. Natl Acad. Sci. USA, 90, 6914-6918.
54. DeCaprio, J.A., Furukawa, Y., Ajchenbaum, F., Griffin, J.D. and Livingston, D.M. (1992) The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc. Natl Acad. Sci. USA, 89, 1795-1798.
55. Hollingsworth, R.E., Chen, P.-L. and Lee, W.-H. (1993) Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein. Curr. Opin. Cell Biol., 5, 194-200.
56. Flaman, J.M., Frebourg, T., Moreau, V. et al. (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl Acad. Sci. USA, 92, 3963-3967.
57. Lamb, P. and Crawford, L. (1986) Characterization of the human p53 gene. Mol. Cell. Biol., 6, 1379-1385.
58. Gudas, J.M., Nguyen, H., Klein, R.C., Katayose, D., Seth, P. and Cowan, K.H. (1995) Differential expression of multiple MDM2 messenger mRNAs and proteins in normal and tumorigenic breast epithelial cells. Clin. Cancer Res., 1, 71-80.
59. Smith, M.L., Chen, I.-T., Zhan, Q., Bae, I., Chen, C.-Y. Gilmer, T.M., Kastan, M.B., O'Connor, P.M. and Fornace, A.J., Jr (1994) Interaction of the p53-regulated protein Gadd 45 with proliferating cell nuclear antigen. Science, 266, 1376-1380.
60. Fan, S., Smith, M.L., Rivet, D.J.N., Duba, D., Zhan, Q., Kohn, K.W., Fornace, A.J., Jr and O'Connor, P.M. (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxyfilline. Cancer Res., 55, 1649-54.
61. Fisher, D.E. (1994) Apoptosis in cancer therapy: crossing the threshold. Cell, 78, 539-542.
62. Martin, S.J. and Green, D.R. (1994) Apoptosis as a goal of cancer therapy. Curr. Opin. Oncol., 6, 616-621.
63. Nelson, W.G. and Kastan, M.B. (1994) DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14, 1815-1823.
64. Wosikowski, K., Regis, J.T., Robey, R.W., Alvarez, M., Buters, J.T.M., Gudas, J.M. and Bates, S.E. (1995) Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differentiat., 6, 1395-1403.
65. Silvestrini, R., Benini, E., Daidone, M.G., Veneroni, S., Boracchi, P., Cappelletti, V., DiFronzo, G. and Veronesi, U. (1993) p53 as an independent prognostic marker in lymph node negative breast cancer patients. J. Natl Cancer Inst., 85, 965-970.
66. Thor, A.D., Moore, D.H.I., Edgerton, S.M. et al. (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst., 84, 845-855.
67. Cunningham, J.M., Ingle, J.N., Jung, S.H. et al. (1994) p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J. Natl Cancer Inst., 86, 1871-1873.
68. Allred, D.C., Clark, G.M., Elledge, R., Fuqua, S.A.W., Brown, R.W., Chamness, G.C., Osborne, C.K. and McGuire, W.L. (1993) Association of p53 expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl Cancer Inst., 85, 200-206.
69. Clarke, R., Dickson, R.B. and Lippman, M.E. (1992) Hormonal aspects of breast cancer: growth factors, drugs and stromal interactions. Crit. Rev. Oncol./Hematol., 12, 1-23.
70. Freiss, G., Prebois, C. and Vignon, F. (1993) Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms. Breast Cancer Res. Treatment, 27, 57-68.
71. Gudas, J.M., Klein, R.C., Oka, M. and Cowan, K.H. (1995) Post-transcriptional regulation of the c-myb protooncogene in estrogen receptor positive breast tumor cells. Clin. Cancer Res., 1, 235-243.
72. Viekers, P.J., Dickson, R.B., Shoemaker, R. and Cowan, K.H. (1988) A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol., 2, 886-892.
73. Maxwell, S.A. and Roth, J.A. (1994) Posttranslational regulation of p53 tumor suppressor protein function. Crit. Rev. Oncogen., 5, 23-57.
74. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W. and Vogelstein, B. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857-860.
75. Juven, T., Barak, Y., Zauberman, A., George, D.L. and Oren, M. (1993) Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene, 8, 3411-3416.
76. Lees-Miller, S.P., Godbout, R., Chan, D.W., Weinfeld, M., Day, R.S.I., Barron, G.M. and Allalunis-Turner, J. (1995) Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science, 267, 1183-1187.
77. Kirchgessner, C.U., Patil, C.K., Evans, J.W., Cuomo, C.A., Fried, L.M., Carter, T., Oettinger, M.A. and Brown, J.M. (1995) DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science, 267, 1178-1183.
78. Smider, V., Rathmell, W.K., Lieber, M.R. and Chu, G. (1994) Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. Science, 266, 288-291.
79. Shaulian, E., Haviv, I., Shaul, Y. and Oren, M. (1995) Transcriptional repression by the C-terminal domain of p53. Oncogene, 10, 671-680.
80. El Rouby, B.S., Thomas, A., Costin, D., Rosenberg, C.R., Potmesil, M., Silber, R. and Newcomb, E.W. (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, 3452-3459.
81. Fan, S., El-Deiry, W.S., Bae, I. et al. (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54, 5824-5830.
82. Petty, R.D., Cree, I.A., Sutherland, L.A., Hunter, E.M., Lane, D.P., Preece, P.E. and Andreotti, P.E. (1994) Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem. Biophys. Res. Commun., 199, 264-270.
83. Slichenmyer, W.J., Nelson, W.G., Slebos, R.J. and Kastan, M.B. (1993) Loss of p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53, 4164-4168.
84. Elledge, R.M., Gray, R., Mansour, E. et al. (1995) Accumulation of p53 protein as a possible predictor to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. Natl Cancer Inst., 87, 1254-1256.
85. Deppert, W. (1994) The yin and yang of p53 in cellular proliferation. Semin. Cancer Biol., 5, 187-202.
86. Guillouf, C., Rosselli, F., Krishnaraju, K., Moustacchi, E., Hoffman, B. and Lieberman, D.A. (1995) p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene, 10, 2263-2270.
87. Miyashita, T. and Reed, J.C. (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemic cell line. Blood, 81, 151-157.
88. Walton, M.I., Whysong, D., O'Connor, P.M., Hockenbery, D. and Korsmeyer, S.J. (1993) Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin-induced apoptosis. Cancer Res., 53, 1853-1861.
89. Dole, M.G., Jasty, R., Cooper, M.J., Thompson, C.B., Nunez, G. and Castle, V.P. (1995) Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55, 2576-2582.
90. Bedi, A., Barber, J.P., Dedi, G.C., El-Diery, W.S., Sidransky, D., Vala, M.S., Akhtar, A.J., Hilton, J. and Jones, R.J. (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86, 1148-1158.
91. Lin, D., Fiscella, M., O'Connor, P.M. et al. (1994) Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc. Natl Acad. Sci. USA, 91, 10079-10083.
92. Kondo, S., Barnett, G.H., Hara, H., Morimura, T. and Takeuchi, J. (1995) MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene, 10, 2001-2006.
93. Zhou, P., Jiang, W., Weghorst, C.M. and Weinstein, I.B. (1996) Overexpression of cyclin D1 enhances gene amplification. Cancer Res., 56, 36-39.
94. Forrester, K., Lupold, S.E., Ott, V.L., Chay, C.H., Band, V., Wang, X.W. and Harris, C.C. (1995) Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10, 2103-2111.